Merits

lab-assistant-glasses-medical-mask-medic
elderly-health-check-with-young-nurse.jp

Reliability

An ideal personal health record platform with both transparency, openness and security enables reliable infection control tracking.

sick-man-corona-virus-looking-through-wi

Economic efficiency

By issuing cryptocurrency, the medical information ecosystem centered on medical consumers will be established by collecting inspection records and health care data of examinees

Verification

Evaluation of the storage and transportation process of samples and kits shall be quantified and the management index of laboratories shall be transparently disclosed to ensure users' choice.

COVID-19 diagnostic kit

There are many regulation systems and acts to prevent pandemic of infectious disease, especially COVID-19, around world. In U.S. At the request of the Centers for Disease Control and Prevention (CDC), the FDA announced the Emergency Use Authorization (EUA), which promotes the development and review of products for diagnosis, treatment and prevention of COVID-19. The EUA is a bill that uses possible medical countermeasures (MCM) in situations where new infectious diseases and public health are threatened by chemical, biological, radiological, and nuclear (CBRN). Under EUA, the Director -General of the FDA may authorize the use of unauthorized medicines and medical devices in emergencies. The FDA granted emergency use approvals for a total of 16 diagnostic kits by March 24 after applying the EUA to COVID-19. 

 

In Korea, the government implements an emergency use approval system that permits the temporary use of medical devices , including diagnostic reagents , if there are no products approved in Korea or supply is insufficient during the pandemic. On January 28, the Korea Centers for Disease Control and Prevention received applications from companies through the "Application for Evaluation of New CoronaVirus Genetic Test Reagent"

 

STILL 

 

COVID-19 has no cure developed, so there is no standard treatment. FDA Director Stephen Hahn noted that it would take three to six months for the development of a formal treatment, and that vaccines would take about a year.